Jeffrey G Supko

Jeffrey G Supko

UNVERIFIED PROFILE

Are you Jeffrey G Supko?   Register this Author

Register author
Jeffrey G Supko

Jeffrey G Supko

Publications by authors named "Jeffrey G Supko"

Are you Jeffrey G Supko?   Register this Author

72Publications

2257Reads

49Profile Views

Acoustic feedback enables safe and reliable carboplatin delivery across the blood-brain barrier with a clinical focused ultrasound system and improves survival in a rat glioma model.

Authors:
Nathan McDannold Yongzhi Zhang Jeffrey G Supko Chanikarn Power Tao Sun Chengueng Peng Natalia Vykhodtseva Alexandra J Golby David A Reardon

Theranostics 2019 14;9(21):6284-6299. Epub 2019 Aug 14.

Department of Medical Oncology, Dana-Farber Cancer Institute; Department of Medicine, Brigham and Women's Hospital; Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.7150/thno.35892DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735504PMC
August 2019

A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer.

Authors:
Atish D Choudhury Kathryn P Gray Jeffrey G Supko Lauren C Harshman Mary-Ellen Taplin Amanda F Pace Matthew Farina Katherine A Zukotynski Brandon Bernard Philip W Kantoff Mark Pomerantz Christopher Sweeney

Prostate 2018 Jun 7. Epub 2018 Jun 7.

Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/pros.23662DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286224PMC
June 2018

Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.

Authors:
Vandana G Abramson Jeffrey G Supko Tarah Ballinger James M Cleary John F Hilton Sara M Tolaney Nicole G Chau Daniel C Cho Joseph Pearlberg Joanne Lager Geoffrey I Shapiro Carlos L Arteaga

Clin Cancer Res 2017 Jul 28;23(14):3520-3528. Epub 2016 Dec 28.

Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-1764DOI Listing
July 2017

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.

Authors:
Dan T Vogl Noopur Raje Sundar Jagannath Paul Richardson Parameswaran Hari Robert Orlowski Jeffrey G Supko David Tamang Min Yang Simon S Jones Catherine Wheeler Robert J Markelewicz Sagar Lonial

Clin Cancer Res 2017 07 4;23(13):3307-3315. Epub 2017 Jan 4.

Emory University, Atlanta, Georgia.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-2526DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496796PMC
July 2017

Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.

Authors:
Matthias Holdhoff Xiaobu Ye Jeffrey G Supko Louis B Nabors Arati S Desai Tobias Walbert Glenn J Lesser William L Read Frank S Lieberman Martin A Lodge Jeffrey Leal Joy D Fisher Serena Desideri Stuart A Grossman Richard L Wahl David Schiff

Neuro Oncol 2017 06;19(6):845-852

University of Virginia Medical Center, Charlottesville, Virginia, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1093/neuonc/nox020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464434PMC
June 2017

Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Authors:
Tracy T Batchelor Elizabeth R Gerstner Xiaobu Ye Serena Desideri Daniel G Duda David Peereboom Glenn J Lesser Sajeel Chowdhary Patrick Y Wen Stuart Grossman Jeffrey G Supko

Neuro Oncol 2017 04;19(4):567-575

Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1093/neuonc/now185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464374PMC
April 2017

Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.

Authors:
Edward Pan Jeffrey G Supko Thomas J Kaley Nicholas A Butowski Timothy Cloughesy Jinkyu Jung Serena Desideri Stuart Grossman Xiaobu Ye Deric M Park

J Neurooncol 2016 12 8;130(3):571-579. Epub 2016 Nov 8.

Neuro-Oncology Branch, CCR, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s11060-016-2263-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571739PMC
December 2016

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.

Authors:
Andrew J Yee William I Bensinger Jeffrey G Supko Peter M Voorhees Jesus G Berdeja Paul G Richardson Edward N Libby Ellen E Wallace Nicole E Birrer Jill N Burke David L Tamang Min Yang Simon S Jones Catherine A Wheeler Robert J Markelewicz Noopur S Raje

Lancet Oncol 2016 Nov 17;17(11):1569-1578. Epub 2016 Sep 17.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/S1470-2045(16)30375-8DOI Listing
November 2016

Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.

Authors:
Ran Xu Fumiko Shimizu Koos Hovinga Kathryn Beal Sasan Karimi Leif Droms Kyung K Peck Philip Gutin J Bryan Iorgulescu Thomas Kaley Lisa DeAngelis Elena Pentsova Craig Nolan Christian Grommes Timothy Chan Dylan Bobrow Adilia Hormigo Justin R Cross Nian Wu Naoko Takebe Katherine Panageas Percy Ivy Jeffrey G Supko Viviane Tabar Antonio Omuro

Clin Cancer Res 2016 Oct 6;22(19):4786-4796. Epub 2016 May 6.

Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

 Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050072PMC
http://dx.doi.org/10.1158/1078-0432.CCR-16-0048DOI Listing
October 2016

Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.

Authors:
Andrew E Place Kristen E Stevenson Lynda M Vrooman Marian H Harris Sarah K Hunt Jane E O'Brien Jeffrey G Supko Barbara L Asselin Uma H Athale Luis A Clavell Peter D Cole Kara M Kelly Caroline Laverdiere Jean-Marie Leclerc Bruno Michon Marshall A Schorin Jennifer J G Welch Steven E Lipshultz Jeffery L Kutok Traci M Blonquist Donna S Neuberg Stephen E Sallan Lewis B Silverman

Lancet Oncol 2015 Dec 6;16(16):1677-90. Epub 2015 Nov 6.

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/S1470-2045(15)00363-0DOI Listing
December 2015

Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.

Authors:
Jaishri O Blakeley Stuart A Grossman Tom Mikkelsen Myrna R Rosenfeld David Peereboom L Burt Nabors Andrew S Chi Gary Emmons Ignacio Garcia Ribas Jeffrey G Supko Serena Desideri Xiaobu Ye

J Neurooncol 2015 Oct 19;125(1):123-31. Epub 2015 Aug 19.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1550 Orleans Street, Suite 1 M-16, Baltimore, MD, 21287, USA.

View Article

Download full-text PDF

 Source
http://link.springer.com/content/pdf/10.1007/s11060-015-1876
Web Search
http://link.springer.com/10.1007/s11060-015-1876-0
Publisher Site
http://dx.doi.org/10.1007/s11060-015-1876-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869687PMC
October 2015

A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.

Authors:
Myrna R Rosenfeld Xiaobu Ye Jeffrey G Supko Serena Desideri Stuart A Grossman Steven Brem Tom Mikkelson Daniel Wang Yunyoung C Chang Janice Hu Quentin McAfee Joy Fisher Andrea B Troxel Shengfu Piao Daniel F Heitjan Kay-See Tan Laura Pontiggia Peter J O'Dwyer Lisa E Davis Ravi K Amaravadi

Autophagy 2014 Aug 20;10(8):1359-68. Epub 2014 May 20.

Division of Hematology-Oncology; Department of Medicine; Perelman School of Medicine; Philadelphia, PA USA; Abramson Cancer Center, University of Pennsylvania; Philadelphia, PA USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.4161/auto.28984DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203513PMC
August 2014

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Authors:
Nikhil Wagle Brian C Grabiner Eliezer M Van Allen Eran Hodis Susanna Jacobus Jeffrey G Supko Michelle Stewart Toni K Choueiri Leena Gandhi James M Cleary Aymen A Elfiky Mary Ellen Taplin Edward C Stack Sabina Signoretti Massimo Loda Geoffrey I Shapiro David M Sabatini Eric S Lander Stacey B Gabriel Philip W Kantoff Levi A Garraway Jonathan E Rosenberg

Cancer Discov 2014 May 13;4(5):546-53. Epub 2014 Mar 13.

Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, 3Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; Departments of 4Medicine and 5Pathology, Brigham and Women's Hospital, Harvard Medical School; 6Division of Hematology/Oncology, Massachusetts General Hospital, Boston; 7Broad Institute of Harvard and MIT; 8Department of Biology, Whitehead Institute for Biomedical Research; 9Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts; and 10Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122326PMC
May 2014

Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer.

Authors:
Brian M Wolpin Kimmie Ng Andrew X Zhu Thomas Abrams Peter C Enzinger Nadine J McCleary Deborah Schrag Eunice L Kwak Jill N Allen Pankaj Bhargava Jennifer A Chan Wolfram Goessling Lawrence S Blaszkowsky Jeffrey G Supko Meaghan Elliot Kaori Sato Eileen Regan Jeffrey A Meyerhardt Charles S Fuchs

Oncologist 2013 11;18(4):377-8. Epub 2013 Apr 11.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1634/theoncologist.2012-0378DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639523PMC
December 2013

Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma.

Authors:
Lipika Goyal Jeffrey G Supko Jordan Berlin Lawrence S Blaszkowsky Amanda Carpenter Douglas M Heuman Sarah L Hilderbrand Keith E Stuart Scott Cotler Neil N Senzer Emily Chan Carl L Berg Jeffrey W Clark Aram F Hezel David P Ryan Andrew X Zhu

Cancer Chemother Pharmacol 2013 Dec;72(6):1305-14

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s00280-013-2293-8DOI Listing
December 2013

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.

Authors:
Wanda L Salzer Barbara Asselin Jeffrey G Supko Meenakshi Devidas Nicole A Kaiser Paul Plourde Naomi J Winick Gregory H Reaman Elizabeth Raetz William L Carroll Stephen P Hunger

Blood 2013 Jul 5;122(4):507-14. Epub 2013 Jun 5.

US Army Medical Research and Materiel Command, Fort Detrick, MD 21702-5012, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1182/blood-2013-01-480822DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724190PMC
July 2013

A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors:
Jennifer R Brown Bradley Messmer Lillian Werner Matthew S Davids Evgeny Mikler Jeffrey G Supko David C Fisher Ann S LaCasce Philippe Armand Eric Jacobsen Virginia Dalton Bethany Tesar Stacey M Fernandes Sean McDonough Jerome Ritz Laura Rassenti Thomas J Kipps Donna Neuberg Arnold S Freedman

Haematologica 2013 Jun 3;98(6):964-70. Epub 2013 May 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.3324/haematol.2013.086207DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669454PMC
June 2013

NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.

Authors:
David M Peereboom Manmeet S Ahluwalia Xiaobu Ye Jeffrey G Supko Sarah L Hilderbrand Surasak Phuphanich L Burt Nabors Myrna R Rosenfeld Tom Mikkelsen Stuart A Grossman

Neuro Oncol 2013 Apr 17;15(4):490-6. Epub 2013 Jan 17.

Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

 Source
https://academic.oup.com/neuro-oncology/article-lookup/doi/1
Publisher Site
http://dx.doi.org/10.1093/neuonc/nos322DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607264PMC
April 2013

A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.

Authors:
Beata Holkova Jeffrey G Supko Matthew M Ames Joel M Reid Geoffrey I Shapiro Edward Brent Perkins Viswanathan Ramakrishnan Mary Beth Tombes Connie Honeycutt Renee M McGovern Maciej Kmieciak Ellen Shrader Martha D Wellons Heidi Sankala Austin Doyle John Wright John D Roberts Steven Grant

Clin Cancer Res 2013 Apr 20;19(7):1873-83. Epub 2013 Mar 20.

Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-2926DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618599PMC
April 2013

Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.

Authors:
Lynda M Vrooman Kristen E Stevenson Jeffrey G Supko Jane O'Brien Suzanne E Dahlberg Barbara L Asselin Uma H Athale Luis A Clavell Kara M Kelly Jeffery L Kutok Caroline Laverdière Steven E Lipshultz Bruno Michon Marshall Schorin Mary V Relling Harvey J Cohen Donna S Neuberg Stephen E Sallan Lewis B Silverman

J Clin Oncol 2013 Mar 28;31(9):1202-10. Epub 2013 Jan 28.

Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, 02215, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2012.43.2070DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595424PMC
March 2013

Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Authors:
Andrew X Zhu Marek Ancukiewicz Jeffrey G Supko Dushyant V Sahani Lawrence S Blaszkowsky Jeffrey A Meyerhardt Thomas A Abrams Nadine Jackson McCleary Pankaj Bhargava Alona Muzikansky Susan Sheehan Eileen Regan Eamala Vasudev Michelle Knowles Charles S Fuchs David P Ryan Rakesh K Jain Dan G Duda

Clin Cancer Res 2013 Mar 29;19(6):1557-66. Epub 2013 Jan 29.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-3041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609423PMC
March 2013

A phase II trial of oral gimatecan for recurrent glioblastoma.

Authors:
Jethro Hu Patrick Y Wen Lauren E Abrey Camilo E Fadul Jan Drappatz Nadia Salem Jeffrey G Supko Fred Hochberg

J Neurooncol 2013 Feb 12;111(3):347-53. Epub 2012 Dec 12.

Johnnie L. Cochran Jr. Brain Tumor Center, 8631 West Third St, Suite 410E, Los Angeles, CA 90048, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s11060-012-1023-0DOI Listing
February 2013

A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.

Authors:
Sarah B Goldberg Jeffrey G Supko Joel W Neal Alona Muzikansky Subba Digumarthy Panos Fidias Jennifer S Temel Rebecca S Heist Alice T Shaw Patricia O McCarthy Thomas J Lynch Sreenath Sharma Jeffrey E Settleman Lecia V Sequist

J Thorac Oncol 2012 Oct;7(10):1602-8

Massachusetts General Hospital Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/JTO.0b013e318262de4aDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3791327PMC
October 2012

Tumor suppression by small molecule inhibitors of translation initiation.

Authors:
Limo Chen Bertal H Aktas Yibo Wang Xiaoying He Rupam Sahoo Nancy Zhang Severine Denoyelle Eihab Kabha Hongwei Yang Revital Yefidoff Freedman Jeffrey G Supko Michael Chorev Gerhard Wagner Jose A Halperin

Oncotarget 2012 Aug;3(8):869-81

Harvard Medical School, USA.

View Article

Download full-text PDF

 Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478463PMC
http://dx.doi.org/10.18632/oncotarget.598DOI Listing
August 2012

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.

Authors:
David S Hong Razelle Kurzrock Jeffrey G Supko Xiaoying He Aung Naing Jennifer Wheler Donald Lawrence Joseph Paul Eder Colin J Meyer Deborah A Ferguson James Mier Marina Konopleva Sergej Konoplev Michael Andreeff Donald Kufe Hillard Lazarus Geoffrey I Shapiro Bruce J Dezube

Clin Cancer Res 2012 Jun 25;18(12):3396-406. Epub 2012 May 25.

Department ofInvestigational Cancer Therapeutics, Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

 Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-11-2703DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494099PMC
June 2012

Phase I study of terameprocol in patients with recurrent high-grade glioma.

Authors:
Stuart A Grossman Xiaobu Ye David Peereboom Myrna R Rosenfeld Tom Mikkelsen Jeffrey G Supko Serena Desideri

Neuro Oncol 2012 Apr 8;14(4):511-7. Epub 2012 Feb 8.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1093/neuonc/nor230DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3309850PMC
April 2012

Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity.

Authors:
Filiberto Cedeno-Laurent Matthew J Opperman Steven R Barthel Danielle Hays Tobias Schatton Qian Zhan Xiaoying He Khushi L Matta Jeffrey G Supko Markus H Frank George F Murphy Charles J Dimitroff

J Invest Dermatol 2012 Feb 8;132(2):410-20. Epub 2011 Dec 8.

Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1038/jid.2011.335DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258338PMC
February 2012

Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target.

Authors:
Ting Chen Duygu Ozel Yuan Qiao Fred Harbinski Limo Chen Séverine Denoyelle Xiaoying He Nela Zvereva Jeffrey G Supko Michael Chorev Jose A Halperin Bertal H Aktas

Nat Chem Biol 2011 Jul 17;7(9):610-6. Epub 2011 Jul 17.

Laboratory for Translational Research, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1038/nchembio.613DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684262PMC
July 2011

A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.

Authors:
David M Peereboom Jeffrey G Supko Kathryn A Carson Tracy Batchelor Surasak Phuphanich Glenn Lesser Tom Mikkelsen Tom Mikkelson Joy Fisher Serena Desideri Xiaoying He Stuart A Grossman

J Neurooncol 2010 Nov 7;100(2):261-8. Epub 2010 May 7.

Cleveland Clinic Brain Tumor and Neuro-Oncology Center, Cleveland, OH, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s11060-010-0190-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811044PMC
November 2010

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.

Authors:
Surasak Phuphanich Jeffrey G Supko Kathryn A Carson Stuart A Grossman L Burt Nabors Tom Mikkelsen Glenn Lesser Steve Rosenfeld Serena Desideri Jeffrey J Olson

J Neurooncol 2010 Oct 8;100(1):95-103. Epub 2010 Mar 8.

The New Approaches to Brain Tumor Therapy Consortium, NABTT Central Office, 1550 Orleans Street, Suite 1M-16, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s11060-010-0143-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811025PMC
October 2010

Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic.

Authors:
Gregory H Bird Navid Madani Alisa F Perry Amy M Princiotto Jeffrey G Supko Xiaoying He Evripidis Gavathiotis Joseph G Sodroski Loren D Walensky

Proc Natl Acad Sci U S A 2010 Aug 21;107(32):14093-8. Epub 2010 Jul 21.

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

 Source
http://www.pnas.org/cgi/doi/10.1073/pnas.1002713107
Publisher Site
http://dx.doi.org/10.1073/pnas.1002713107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922607PMC
August 2010

Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme.

Authors:
Matthias Holdhoff Jeffrey G Supko Gary L Gallia Christine L Hann David Bonekamp Xiaobu Ye Bing Cao Alessandro Olivi Stuart A Grossman

J Neurooncol 2010 Apr 19;97(2):241-5. Epub 2009 Sep 19.

Brain Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Cancer Research Building II, Suite 1 M-16 1550 Orleans Street, Baltimore, MD, 21231, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s11060-009-0008-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3927643PMC
April 2010

Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.

Authors:
Lynda M Vrooman Jeffrey G Supko Donna S Neuberg Barbara L Asselin Uma H Athale Luis Clavell Kara M Kelly Caroline Laverdière Bruno Michon Marshall Schorin Harvey J Cohen Stephen E Sallan Lewis B Silverman

Pediatr Blood Cancer 2010 Feb;54(2):199-205

Department of Pediatric Oncology, Biostatistics, and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/pbc.22225DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706086PMC
February 2010

Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.

Authors:
Lewis B Silverman Jeffrey G Supko Kristen E Stevenson Christina Woodward Lynda M Vrooman Donna S Neuberg Barbara L Asselin Uma H Athale Luis Clavell Peter D Cole Kara M Kelly Caroline Laverdière Bruno Michon Marshall Schorin Cindy L Schwartz Jane E O'Brien Harvey J Cohen Stephen E Sallan

Blood 2010 Feb 10;115(7):1351-3. Epub 2009 Dec 10.

Departments of Pediatric Oncology, Biostatistics, and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1182/blood-2009-09-245951DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2826760PMC
February 2010

Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.

Authors:
Panos Fidias Nathan A Pennell Anthony L Boral Geoffrey I Shapiro Arthur T Skarin Joseph P Eder T Jesse Kwoh Richard S Geary Bruce E Johnson Thomas J Lynch Jeffrey G Supko

J Thorac Oncol 2009 Sep;4(9):1156-62

Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/JTO.0b013e3181b2793fDOI Listing
September 2009

Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.

Authors:
Mark W Kieran Jeffrey G Supko Dana Wallace Robert Fruscio Tina Young Poussaint Peter Phillips Ian Pollack Roger Packer James M Boyett Susan Blaney Anu Banerjee Russ Geyer Henry Friedman Stewart Goldman Larry E Kun Tobey Macdonald

Pediatr Blood Cancer 2009 Feb;52(2):169-76

Pediatric Neuro-Oncology Program, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/pbc.21873DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2775441PMC
February 2009

Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study.

Authors:
Jaishri O Blakeley Jeffrey Olson Stuart A Grossman Xiaoying He Jon Weingart Jeffrey G Supko

J Neurooncol 2009 Jan 12;91(1):51-8. Epub 2008 Sep 12.

Johns Hopkins University School of Medicine, Cancer Research Building II, 1550 Orleans Street, Suite 1M16, Baltimore, MD, 21231, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s11060-008-9678-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029102PMC
January 2009

Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.

Authors:
Andrew X Zhu Neal Ready Jeffrey W Clark Howard Safran Antonino Amato Nadia Salem Silvia Pace Xiaoying He Nela Zvereva Thomas J Lynch David P Ryan Jeffrey G Supko

Clin Cancer Res 2009 Jan;15(1):374-81

Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-1024DOI Listing
January 2009

Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.

Authors:
Stuart A Grossman Kathryn A Carson Surasak Phuphanich Tracy Batchelor David Peereboom L Burt Nabors Glenn Lesser Fredrick Hausheer Jeffrey G Supko

Neuro Oncol 2008 Aug 24;10(4):608-16. Epub 2008 Jun 24.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231-1000, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1215/15228517-2008-030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2666235PMC
August 2008

Identification of the in vitro metabolites of 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (ARQ 501; beta-lapachone) in whole blood.

Authors:
Xiu-Sheng Miao Pengfei Song Ronald E Savage Caiyun Zhong Rui-Yang Yang Darin Kizer Hui Wu Erika Volckova Mark A Ashwell Jeffrey G Supko Xiaoying He Thomas C K Chan

Drug Metab Dispos 2008 Apr 7;36(4):641-8. Epub 2008 Jan 7.

Department of Preclinical Development and Clinical Pharmacology, ArQule, Inc., Woburn, Massachusetts 01801, USA.

View Article

Download full-text PDF

 Source
http://dmd.aspetjournals.org/cgi/doi/10.1124/dmd.107.018572
Publisher Site
http://dx.doi.org/10.1124/dmd.107.018572DOI Listing
April 2008

Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.

Authors:
Stuart A Grossman Jeffrey Olson Tracy Batchelor David Peereboom Glenn Lesser Serena Desideri Xiaobu Ye Tarek Hammour Jeffrey G Supko

Neuro Oncol 2008 Apr 20;10(2):190-8. Epub 2008 Feb 20.

NABTT CNS Consortium, 1550 Orleans Street, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

 Source
http://academic.oup.com/neuro-oncology/article/10/2/190/1076
Publisher Site
http://dx.doi.org/10.1215/15228517-2007-055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613821PMC
April 2008

Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.

Authors:
Eyal C Attar Daniel J De Angelo Jeffrey G Supko Ferdinando D'Amato David Zahrieh Andres Sirulnik Martha Wadleigh Karen K Ballen Steve McAfee Kenneth B Miller James Levine Ilene Galinsky Elizabeth G Trehu David Schenkein Donna Neuberg Richard M Stone Philip C Amrein

Clin Cancer Res 2008 Mar;14(5):1446-54

Hematology/Oncology Unit, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-4626DOI Listing
March 2008

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.

Authors:
Ultan McDermott Sreenath V Sharma Lori Dowell Patricia Greninger Clara Montagut Jennifer Lamb Heidi Archibald Raul Raudales Angela Tam Diana Lee S Michael Rothenberg Jeffrey G Supko Raffaella Sordella Lindsey E Ulkus A John Iafrate Shyamala Maheswaran Ching Ni Njauw Hensin Tsao Lisa Drew Jeff H Hanke Xiao-Jun Ma Mark G Erlander Nathanael S Gray Daniel A Haber Jeffrey Settleman

Proc Natl Acad Sci U S A 2007 Dec 6;104(50):19936-41. Epub 2007 Dec 6.

Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1073/pnas.0707498104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2148401PMC
December 2007

Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.

Authors:
Jeffrey A Meyerhardt Jeffrey W Clark Jeffrey G Supko Joseph P Eder Shuji Ogino Clinton F Stewart Ferdinando D'Amato Janet Dancey Peter C Enzinger Andrew X Zhu David P Ryan Craig C Earle Robert J Mayer Ann Michelini Kate Kinsella Charles S Fuchs

Cancer Chemother Pharmacol 2007 Oct 11;60(5):661-70. Epub 2007 Jan 11.

Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s00280-006-0411-6DOI Listing
October 2007

Exposure to phytoestrogens in the perinatal period affects androgen secretion by testicular Leydig cells in the adult rat.

Authors:
Benson T Akingbemi Tim D Braden Barbara W Kemppainen Karen D Hancock Jessica D Sherrill Sarah J Cook Xiaoying He Jeffrey G Supko

Endocrinology 2007 Sep 14;148(9):4475-88. Epub 2007 Jun 14.

Department of Anatomy, Physiology and Pharmacology, 109 Greene Hall, Auburn University, Auburn, Alabama 36849, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1210/en.2007-0327DOI Listing
September 2007

Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome.

Authors:
Serene S Srouji Yanira L Pagán Fernando D'Amato Amsalu Dabela Yarisie Jimenez Jeffrey G Supko Janet E Hall

J Clin Endocrinol Metab 2007 Apr 30;92(4):1347-52. Epub 2007 Jan 30.

Reproductive Endocrine Unit, BHX-5, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1210/jc.2006-2716DOI Listing
April 2007

Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.

Authors:
Anna Berkenblit Joseph P Eder David P Ryan Michael V Seiden Noriaki Tatsuta Matthew L Sherman Thomas A Dahl Bruce J Dezube Jeffrey G Supko

Clin Cancer Res 2007 Jan;13(2 Pt 1):584-90

Beth Israel Deaconess Medical Center, and Harvard Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-0964DOI Listing
January 2007

A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.

Authors:
David P Ryan Bert H O'Neil Jeffrey G Supko Carlo M Rocha Lima E Claire Dees Leonard J Appleman Jeffrey Clark Phinos Fidias Robert Z Orlowski Oscar Kashala Joseph P Eder James C Cusack

Cancer 2006 Dec;107(11):2688-97

Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.22280DOI Listing
December 2006

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.

Authors:
David P Ryan Leonard J Appleman Thomas Lynch Jeffrey G Supko Panagiotis Fidias Jeffrey W Clark Mayer Fishman Andrew X Zhu Peter C Enzinger Oscar Kashala James Cusack Joseph P Eder

Cancer 2006 Nov;107(10):2482-9

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.22264DOI Listing
November 2006

The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride.

Authors:
Stuart A Grossman Kathryn A Carson Tracy T Batchelor Glenn Lesser Tom Mikkelsen Jane B Alavi Surasak Phuphanich Tarek Hammour Joy D Fisher Jeffrey G Supko

Clin Cancer Res 2006 Sep;12(17):5174-81

The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231-1000, and Massachusetts General Hospital, Boston, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-0932DOI Listing
September 2006

Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.

Authors:
Joseph P Eder David P Ryan Leonard Appleman Andrew X Zhu Thomas Puchalski Xiaoying He Daryl S Sonnichsen Michael Cooper John Wright Jeffrey W Clark Jeffrey G Supko

Cancer Chemother Pharmacol 2006 Jul 13;58(1):107-16. Epub 2005 Dec 13.

Dana-Farber Cancer Institute, Department of Medical Oncology and Brigham and Women's Hospital, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Shields-Warren Building 460, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s00280-005-0134-0DOI Listing
July 2006

Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis.

Authors:
Carolyn N Krasner Maria Roche Neil S Horowitz Jeffrey G Supko Susanna I Lee Esther Oliva

N Engl J Med 2006 Apr;354(15):1615-25

Gillette Center for Women's Cancers, Massachusetts General Hospital, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1056/NEJMcpc069002DOI Listing
April 2006

Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.

Authors:
Amber Klein Xiaoying He Maria Roche Allison Mallett Linda Duska Jeffrey G Supko Michael V Seiden

Gynecol Oncol 2006 Jan 19;100(1):205-9. Epub 2005 Sep 19.

Division of Medical Oncology, Massachusetts General Hospital, Cox 640, 100 Blossom Street, Boston, MA 02114, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.ygyno.2005.08.006DOI Listing
January 2006

Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.

Authors:
Philip C Amrein John R Clark Jeffrey G Supko Richard L Fabian Chiu C Wang A Dimitrios Colevas Marshall R Posner Daniel G Deschler James W Rocco Dianne M Finkelstein James F McIntyre

Cancer 2005 Oct;104(7):1418-27

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.21312DOI Listing
October 2005

Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.

Authors:
John R Goffin Ian C Anderson Jeffrey G Supko Joseph Paul Eder Geoffrey I Shapiro Thomas J Lynch Margaret Shipp Bruce E Johnson Arthur T Skarin

Clin Cancer Res 2005 May;11(9):3417-24

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-2144DOI Listing
May 2005

Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.

Authors:
Jaime R Merchan Deepa R Jayaram Jeffrey G Supko Xiaoying He Glenn J Bubley Vikas P Sukhatme

Int J Cancer 2005 Jan;113(3):490-8

Division of Hematology-Oncology, Department of Medicine, the Center for Study of the Tumor Microenvironment, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/ijc.20595DOI Listing
January 2005

Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.

Authors:
Stuart A Grossman Jane B Alavi Jeffrey G Supko Kathryn A Carson Regina Priet F Andrew Dorr John S Grundy Jon T Holmlund

Neuro Oncol 2005 Jan;7(1):32-40

The New Approaches to Brain Tumor Therapy CNS Consortium, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1215/S1152851703000353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1871621PMC
January 2005

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:
Thomas J Lynch Daphne W Bell Raffaella Sordella Sarada Gurubhagavatula Ross A Okimoto Brian W Brannigan Patricia L Harris Sara M Haserlat Jeffrey G Supko Frank G Haluska David N Louis David C Christiani Jeff Settleman Daniel A Haber

N Engl J Med 2004 May 29;350(21):2129-39. Epub 2004 Apr 29.

Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1056/NEJMoa040938DOI Listing
May 2004

A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.

Authors:
Joseph P Eder Rocio Garcia-Carbonero Jeffrey W Clark Jeffrey G Supko Thomas A Puchalski David P Ryan Pamela Deluca Antoinette Wozniak Angela Campbell John Rothermel Patricia LoRusso

Invest New Drugs 2004 Apr;22(2):139-50

Dana-Farber/Harvard Cancer Care, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1023/B:DRUG.0000011790.31292.efDOI Listing
April 2004

Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.

Authors:
David P Ryan Joseph P Eder Thomas Puchlaski Michael V Seiden Thomas J Lynch Charles S Fuchs Philip C Amrein Darrell Sonnichsen Jeffrey G Supko Jeffrey W Clark

Clin Cancer Res 2004 Apr;10(7):2222-30

Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

 Source
April 2004

Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.

Authors:
Andrew X Zhu Thomas A Puchalski Vincent P Stanton David P Ryan Jeffrey W Clark Steven Nesbitt Olga Charlat Patrick Kelly Elaine Kreconus Bruce A Chabner Jeffrey G Supko

Clin Colorectal Cancer 2004 Feb;3(4):225-34

Massachusetts General Hospital, Division of Hematology/Oncology, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.3816/CCC.2004.n.003DOI Listing
February 2004

Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

Authors:
Tracy T Batchelor Mark R Gilbert Jeffrey G Supko Kathryn A Carson Louis B Nabors Stuart A Grossman Glenn J Lesser Tom Mikkelsen Surasak Phuphanich

Neuro Oncol 2004 Jan;6(1):21-7

Brain Tumor Center, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1215/s1152851703000218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1871974PMC
January 2004

Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.

Authors:
Jeffrey G Supko Joseph P Eder David P Ryan Michael V Seiden Thomas J Lynch Phillip C Amrein Donald W Kufe Jeffrey W Clark

Clin Cancer Res 2003 Nov;9(14):5178-86

Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

 Source
November 2003

Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors.

Authors:
Susanna M Campos Ursula A Matulonis Richard T Penson Hang Lee Ross S Berkowitz Linda R Duska Arlan F Fuller Kara S Wilson Thomas A Puchalski Jeffrey G Supko Michael V Seiden

Gynecol Oncol 2003 Sep;90(3):610-8

Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/s0090-8258(03)00373-1DOI Listing
September 2003

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.

Authors:
Caroline Laverdiere E Anders Kolb Jeffrey G Supko Richard Gorlick Paul A Meyers Robert G Maki Leonard Wexler George D Demetri John H Healey Andrew G Huvos Allen M Goorin Rochelle Bagatell Ana Ruiz-Casado Cecilia Guzman Jose Jimeno David Harmon

Cancer 2003 Aug;98(4):832-40

Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.11563DOI Listing
August 2003

Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.

Authors:
Mark R Gilbert Jeffrey G Supko Tracy Batchelor Glenn Lesser Joy D Fisher Steven Piantadosi Stuart Grossman

Clin Cancer Res 2003 Aug;9(8):2940-9

Emory University School of Medicine, Atlanta, Georgia 30322, USA.

View Article

Download full-text PDF

 Source
August 2003

A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.

Authors:
David P Ryan Thomas Puchalski Jeffrey G Supko David Harmon Robert Maki Rocio Garcia-Carbonero Caroline Kuhlman Jennifer Winkelman Priscilla Merriam Travis Quigley Jose Jimeno Judith Manola George D Demetri

Oncologist 2002 ;7(6):531-8

Division of Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1634/theoncologist.7-6-531DOI Listing
February 2003

A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.

Authors:
M Dror Michaelson David P Ryan Charles S Fuchs Jeffrey G Supko Rocio Garcia-Carbonero J Paul Eder Jeffrey W Clark

Cancer 2003 Jan;97(1):148-54

Department of Hematology/Oncology, Massachusetts General Hospital, Cox Building Room 640, 100 Blossom Street, Boston, MA 02114, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.11038DOI Listing
January 2003

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.

Authors:
Thomas A Puchalski David P Ryan Rocio Garcia-Carbonero George D Demetri Leah Butkiewicz David Harmon Michael V Seiden Robert G Maki Luis Lopez-Lazaro Jose Jimeno Cecilia Guzman Jeffrey G Supko

Cancer Chemother Pharmacol 2002 Oct 31;50(4):309-19. Epub 2002 Jul 31.

Dana-Farber/Partners Cancer Care, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s00280-002-0498-3DOI Listing
October 2002

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

Authors:
Joseph P Eder Jeffrey G Supko Jeffrey W Clark Thomas A Puchalski Rocio Garcia-Carbonero David P Ryan Lawrence N Shulman Joann Proper Moira Kirvan Barbara Rattner Susan Connors Mary T Keogan Milos J Janicek William E Fogler Lowell Schnipper Nancy Kinchla Carolyn Sidor Eric Phillips Judah Folkman Donald W Kufe

J Clin Oncol 2002 Sep;20(18):3772-84

Division of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

 Source
http://jco.ascopubs.org/content/20/18/3772.full.pdf
Web Search
http://dx.doi.org/10.1200/JCO.2002.02.082DOI Listing
September 2002

Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.

Authors:
Rocio Garcia-Carbonero Jeffrey G Supko

Clin Cancer Res 2002 Mar;8(3):641-61

Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

 Source
March 2002

A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.

Authors:
Michael V Seiden Shu-Wing Ng Jeffrey G Supko David P Ryan Jeffrey W Clark Thomas Lynch Kuan-Chun Huang David Kwiatkowski Arthur Skarin Joseph P Eder

Clin Cancer Res 2002 Mar;8(3):691-7

Department of Medicine, Massachusetts General Hospital, Boston 02114, USA.

View Article

Download full-text PDF

 Source
March 2002